The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics
and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Author(s): Mendell J(1), Lee F, Chen S, Worland V, Shi M, Samama MM.
Affiliation(s): Author information:
(1)Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA. jmendell@dsi.com
Publication date & source: 2013, J Cardiovasc Pharmacol. , 62(2):212-21
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke
prevention in patients with atrial fibrillation, an elderly population that
frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for
concurrent illnesses. Three studies were conducted to evaluate the
pharmacokinetic and pharmacodynamic interactions of edoxaban 60 mg coadministered
with low-dose (100 mg) ASA, high-dose (325 mg) ASA, or naproxen (500 mg) in
healthy subjects (n = 126). Template bleeding times (BT) were measured. Mean
baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes.
Edoxaban administered alone increased BT by 21%-35% (4 hours post dose) from
baseline. Concomitant administration of edoxaban with high-dose ASA, low-dose
ASA, or naproxen increased BT approximately 2-fold showing an additive effect
greater than either agent administered alone. Edoxaban pharmacokinetics were not
affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased
systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on
prothrombin time, activated partial thromboplastin time, international normalized
ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration
with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA,
low-dose ASA, or naproxen was not affected by edoxaban. Concomitant
administration of edoxaban and ASA or naproxen was well tolerated.
|